Board of Directors at its meeting held today on 04.11.2025 interalia approved Unaudited Financial results (both standalone and consolidated) for the quarter/half year ended 30.09.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sunil Healthcare's Board approved unaudited standalone and consolidated results for Q2 and H1 FY26 on November 4, 2025. Standalone revenue from operations grew to ₹2,351.76 lakhs in Q2 FY26 from ₹2,264.20 lakhs in Q2 FY25 (~3.9% growth), while H1 FY26 revenue rose to ₹4,615.96 lakhs from ₹4,175.32 lakhs (~10.6% growth). On the profit front, the company swung to a small standalone profit of ₹15.10 lakhs in Q2 FY26 from a loss of ₹112.72 lakhs in Q2 FY25. However, H1 FY26 standalone bottom line remained in the red at a loss of ₹32.38 lakhs, though significantly improved from a loss of ₹123.96 lakhs in H1 FY25. Limited review was carried out by Singhi & Co., who issued an unqualified clean review report on both sets of results.
Mildly positive — the company returned to profit on a quarterly basis and sharply narrowed its half-yearly losses, suggesting operational improvement. However, H1 remains in the red and revenue growth is modest, so the results are unlikely to trigger a strong re-rating on their own.